Interferon free treatment Hepatocellular carcinoma prevention Reduced side effects Sustained viral response Virologic cure for hepatitis C Interferon-free treatment, due to the development of direct-acting antiviral agents, represented a key-point regarding the therapy of hepatitis C and the prevention of hepatocellular carcinoma. Introduction Case report » female patient, 58 y.o. » hepatic cirrhosis , Fibro test score = 0.88, F4 » treatment regimen: Dasabuvir 250 mg - 1cpx 2/a day, Ombitasvir/ Paritaprevir/ Ritonavir 12,5 mg/ 75 mg/ 50 mg – 2 cp/a day, 3 months » double valve replacement with mechanical prostheses→ oral anticoagulation Treatment initiation 802 UI/ml Week 12 of treatment Undetectable 12 weeks following the end of the treatment Results and discussion After 1 year Portal vein thrombosis (INR: 4,7-5,9) Hepatocelullar carcinoma Conclusions Interferon-free treatment → possible cause of portal vein thrombosis Hepatocelullar carcinoma → procoagulant status→ portal vein thrombosis Interferon-free treatment – risk factor for the portal vein thrombosis? Ruxandra Lazăr¹,Luminița Confederat¹, Irina Gîrleanu1,² ¹ “Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Medicine- Iași, Romania ² Institute of Gastroenterology and Hepatology – Iași, Romania